1. Volume 150, Issue 2, Pages 419-429 (February 2016)
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection 
Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, Jama M. Darling, Jordan J. Feld, Robert S. Brown, Lynn M. Frazier, Thomas G. Stewart, Michael W. Fried, David R. Nelson, Ira M. Jacobson N. Afdhal, I. Alam, Z. Ben-Ari, J. Bredfeldt, R.S. Brown, R.T. Chung, J. Darling, W. Harlan, A.M. Di Bisceglie, R.C. Dickson, H.A. Elbeshbeshy, G. Everson, J. Feld, J.M. Fenkel, M.W. Fried, J. Galati, S.C. Gordon, M. Hassan, T.N. Hawkins, F. Hinestrosa, I.M. Jacobson, C.A. Kerr, A. Kuo, P.Y. Kwo, J. Levitsky, J. Lim, A.S. Lok, M. Mailliard, M.P. Manns, G. Morelli, A.J. Muir, D. Nelson, J.G. O’Leary, B.L. Pearlman, P. Pockros, A. Ramani, N. Reau, K.R. Reddy, E.R. Schiff, K.E. Sherman, M.L. Shiffman, C. Smith, J.R. Spivey, R.K. Sterling, M.S. Sulkowski, G. Szabo, N.A. Terrault, C. Trautwein, H.E. Vargas, K. Watts, A. Williams, S. Zeuzem Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, Jama M. Darling, Jordan J. Feld, Robert S. Brown, Lynn M. Frazier, Thomas G. Stewart, Michael W. Fried, David R. Nelson, Ira M. Jacobson N. Afdhal, I. Alam, Z. Ben-Ari, J. Bredfeldt, R.S. Brown, R.T. Chung, J. Darling, W. Harlan, A.M. Di Bisceglie, R.C. Dickson, H.A. Elbeshbeshy, G. Everson, J. Feld, J.M. Fenkel, M.W. Fried, J. Galati, S.C. Gordon, M. Hassan, T.N. Hawkins, F. Hinestrosa, I.M. Jacobson, C.A. Kerr, A. Kuo, P.Y. Kwo, J. Levitsky, J. Lim, A.S. Lok, M. Mailliard, M.P. Manns, G. Morelli, A.J. Muir, D. Nelson, J.G. O’Leary, B.L. Pearlman, P. Pockros, A. Ramani, N. Reau, K.R. Reddy, E.R. Schiff, K.E. Sherman, M.L. Shiffman, C. Smith, J.R. Spivey, R.K. Sterling, M.S. Sulkowski, G. Szabo, N.A. Terrault, C. Trautwein, H.E. Vargas, K. Watts, A. Williams, S. Zeuzem 
Gastroenterology 
Volume 150, Issue 2, Pages (February 2016)
DOI: /j.gastro
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
Unadjusted SVR12, multiply imputed for patients treated with simeprevir plus sofosbuvir without ribavirin. (A) Population: patients which completed a full course of treatment or prematurely discontinued treatment for virological reasons (n = 812). SVR12 estimates were calculated with multiple imputation methods to account for 52 of 812 patients with unknown outcomes. (B) Population: patients which completed a full course of treatment or prematurely discontinued treatment for virological reasons (n = 163). SVR12 estimates were calculated with multiple imputation methods to account for 13 of 163 patients with unknown outcomes. (C) Population: patients which completed a full course of treatment or prematurely discontinued treatment for virological reasons (n = 649). SVR12 estimates were calculated with multiple imputation methods to account for 39 of 649 patients with unknown outcomes.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
Model-adjusted estimates of SVR12 among patients treated with simeprevir plus sofosbuvir with or without ribavirin.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

4. Figure 3
Odds ratio estimates from logistic regression models of SVR12 and baseline factors for patients treated with simeprevir plus sofosbuvir with or without ribavirin. Odds ratios are adjusted for regimen (+R v. −R), genotype (1a vs 1b), gender (male vs female), and age. Each line represents a unique model. Observations are weighted with the inverse of probability of treatment weights.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions